Lyell Immunopharma首席财务官Newton以$111,620购入普通股
近期，Lyell Immunopharma, Inc.（NASDAQ:LYEL）首席财务官Newton Charles W.通过一项交易购入了20万股公司普通股。这些股票的加权平均购买价格为$0.5581，总交易金额约为$111,620。此次购买发生之际，该公司股票正在接近52周低点，过去一年股价下跌超过76%。根据 InvestingPro ...
Lyell Immunopharma董事Richard Klausner斥资94,942美元增持公司股票
Lyell Immunopharma, Inc.（NASDAQ:LYEL）董事Richard Klausner近期增持了公司158,000股普通股。这些股票于3月14日以加权平均价0.6009美元购入，交易总额约为94,942美元。此次购买发生之际，LYEL股价接近52周低点0.48美元，仅在过去一周就下跌了近28%。根据InvestingPro数据显示，该股票在过去六个月内下跌了约69%。
美股内部交易 | Lyell Immunopharma于3月18日披露3笔公司内部人交易情况
2025年3月18日， Lyell Immunopharma（LYEL）披露3笔公司内部人交易情况。高管Newton Charles W.于2025年3月17日买入20.00万股。 Lyell Immunopharma, ...
Q1 EPS Estimate for Lyell Immunopharma Boosted by Analyst
Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Lyell Immunopharma in a research note issued on Thursday, March 13th. HC Wainwright analyst M.
American Association of Individual Investors2 天
Why Lyell Immunopharma, Inc.’s (LYEL) Stock Is Down 11.67%
Lyell Immunopharma, Inc.’s LYEL share price has dipped by 11.67%, which has investors questioning if this is right time to buy.
Lyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last year
Reports cash, cash equivalents and marketable securities as of December 31 were $383.5M compared to $562.7M as of December 31, 2023. Lyell ...
The Manila Times7 天
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter ...
Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the ...